(1S,3S,5S)-3-(hydroxymethyl)-2-azabicyclo-<3.3.0>-octane hydrochloride | 162679-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (1S,3S,5S)-3-(hydroxymethyl)-2-azabicyclo-<3.3.0>-octane hydrochloride
• 英文别名: (2S,3aS,6aS)-1-(octahydro-cyclopenta[b]pyrrol-2-yl)-methanol hydrochloride；[(2S,3aS,6aS)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-2-yl]methanol;hydrochloride
• CAS: 162679-02-9
• 化学式: C₈H₁₅NO*ClH
• 分子量: 177.674
• InChiKey: MIBZESIRGSZTEU-WQYNNSOESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二苯基氯化膦 、 (1S,3S,5S)-3-(hydroxymethyl)-2-azabicyclo-<3.3.0>-octane hydrochloride 在 三乙胺 作用下， 以 苯 为溶剂， 反应 3.0h， 以65%的产率得到(1S,3S,5S)-O,N-bis-(diphenylphosphino)-3-hydroxymethyl-2-azabicyclo-<3.3.0>-octane
  参考文献：
  名称：

  Enantioselective hydrogenation using a rigid bicyclic aminophosphine phosphinite ligand

  摘要：

  Crystalline and in situ formed Rh-complexes from (1R,3R,5R)-O,N-bis-(diphenylphosphino)-3 -hydroxymethyl-2-azabicyclo-[3.3.0.]-octane and from the all (S)-enantiomer have been prepared and used in model assymmetric hydrogenations. The catalysts are highly active but the rigidity of their backbone does not contribute to an enhanced stereoselectivity. The ligand is readily available from an intermediate of the Ramipril synthesis the latter being a ACE inhibitor.

  DOI：

  10.1016/0957-4166(95)00020-p
• 作为产物：
  描述：

  2-氮杂双环[3.3.0]辛烷-3-甲酸 生成 (1S,3S,5S)-3-(hydroxymethyl)-2-azabicyclo-<3.3.0>-octane hydrochloride
  参考文献：
  名称：

  WO2007/71393

  摘要：

  公开号：

文献信息

• Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors
  申请人：Capraro Hans-Georg

  公开号：US20080261973A1

  公开（公告）日：2008-10-23

  The invention relates to sulphonamidoanilines of formula I, wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R 1 represents NR 4 R 5 or OR 4 , wherein R 4 represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or two nitrogen or oxygen atoms, or substituted aryl, and R 5 represents hydrogen or unsubstituted or substituted alky, or R 4 and R 5 together with the nitrogen to which they are attached represent an optionally substituted five- or six-membered nitrogen containing monocyclic ring, an optionally substituted nitrogen containing fully saturated bicyclic ring, or an spirocyclic fully saturated ring system containing one or two nitrogen atoms, R 2 is hydrogen, lower alkenyl or alkyl, R 3 is alkyl which is unsubstituted or mono-, di- or trisubstituted by halogen; alkenyl or aryl, and their salts; processes for their preparation, their application in the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of diseases, a method for the treatment of such a disease and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.

  本发明涉及式I的磺酰胺苯胺，其中A为N或CH，W、X、Y和Z为N或CH，但至少三个符号W、X和Y中的一个代表CH，R1代表NR4R5或OR4，其中R4代表可选取代的烷基，可选取代的环烷基，可包含一个或两个氮或氧原子的取代芳基；R5代表氢或未取代或取代的烷基，或R4和R5连同它们所连接的氮表示一个可选取代的五元或六元含氮单环环，一个可选取代的含氮完全饱和的双环环，或一个含有一或两个氮原子的螺环完全饱和环系统，R2为氢、低碳烯基或烷基，R3为未取代或单、二、三取代的卤素的烷基、烯基或芳基，以及它们的盐；它们的制备方法，它们在治疗人体或动物体中的应用，使用它们-独自或与一个或多个其他药理活性化合物结合-治疗疾病的方法，以及使用这种化合物-独自或与一个或多个其他药理活性化合物结合-制造治疗增殖性疾病的药物制剂。
• SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS
  申请人：Novartis AG

  公开号：EP1966210A2

  公开（公告）日：2008-09-10
• [EN] SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS<br/>[FR] DERIVES SULPHONAMIDOANILINE CONSTITUANT DES INHIBITEURS DES JANUS KINASES
  申请人：NOVARTIS AG

  公开号：WO2007071393A2

  公开（公告）日：2007-06-28

  [EN] The invention relates to sulphonamidoanilines of formula (I) wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R¹ represents NR₄R₅ or OR₄, wherein R₄ represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or two nitrogen or oxygen atoms, or substituted aryl, and R₅ represents hydrogen or unsubstituted or substituted alkyl, or R₄ and R₅ together with the nitrogen to which they are attached represent an optionally substituted five- or six-membered nitrogen containing monocyclic ring, an optionally substituted nitrogen containing fully saturated bicyclic ring, or an spirocyclic fully saturated ring system containing one or two nitrogen atoms, R² is hydrogen, lower alkenyl or alkyl, R³ is alkyl which is unsubstituted or mono-, di- or trisubstituted by halogen; alkenyl or aryl, and their salts; processes for their preparation, their application in the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment of diseases, a method for the treatment of such a disease and the use of such a compound - alone or in combination with one or more other pharmaceutically active compounds - for the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.
  [FR] La présente invention concerne des sulphonamidoanilines représentés par la formule générale (I) ou certains de leurs sels. Dans cette formule, A est N ou CH, W, X, Y et Z sont N ou CH, l'un au moins des symboles W, X ou Y devant représenter CH. R¹ est NR₄R₅ ou OR₄, R₄ étant alkyle éventuellement substitué, cycloalkyle éventuellement substitué comprenant éventuellement au moins un atome d'azote ou d'oxygène, ou aryle substitué. R₅ est hydrogène ou alkyle non substitué ou substitué. Mais aussi, R₄ et R₅ avec l'azote auquel ils sont attachés peuvent être un noyau monocyclique azoté à 5 ou 6 segments, éventuellement substitué, un noyau bicyclique azoté totalement saturé et éventuellement substitué, ou un système de noyaux spirocycliques totalement saturés contenant un ou deux atomes d'azote. R² est hydrogène, alcényle inférieur ou alkyle. R³ est alkyle non substitué, ou mono-, di- ou trisubstitué par un halogène, alcényle ou aryle. L'invention concerne également des procédés pour leur élaboration, leur application au traitement du corps humain ou animal, leur utilisation, seuls ou en association avec un ou plusieurs autres composés pharmaceutiquement actifs, pour le traitement de maladie, un procédé pour le traitement d'une telle maladie, et l'utilisation d'un tel composé, seul ou en association avec un ou plusieurs autres composés pharmaceutiquement actifs, pour la fabrication d'une préparation pharmaceutique destinée au traitement d'une maladie proliférante.